Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Killock

Showing results (191-200 of 304) with videos related to

Pageof 31
Sort By:
Nature Reviews. Clinical Oncology|November 28, 2018
Second elotuzumab triplet efficacious in MMDavid Killock
Nature Reviews. Rheumatology|February 6, 2013
Metabolic bone diseases: Building bone is best in glucocorticoid-induced osteoporosisDavid Killock
Nature Reviews. Clinical Oncology|August 13, 2014
Drug therapy: keeping rats in the dark sheds light on tamoxifen resistanceDavid Killock
Nature Reviews. Clinical Oncology|October 15, 2014
Lung cancer: alternative rearrangements--targeting ROS1 in NSCLCDavid Killock
Nature Reviews. Clinical Oncology|June 11, 2026
From ASCO 2026David Killock
Nature Reviews. Clinical Oncology|December 21, 2016
Liver cancer: Regorafenib - a new RESORCE in HCCDavid Killock
Nature Reviews. Clinical Oncology|November 3, 2016
In the news: From ESMO 2016David Killock
Nature Reviews. Urology|February 5, 2014
Kidney cancer: Sunitinib has similar efficacy irrespective of age in mRCCDavid Killock
Nature Reviews. Clinical Oncology|April 23, 2014
Chemotherapy: life gained, years lost?David Killock
Nature Reviews. Urology|March 19, 2014
Prostate cancer: substratification of intermediate-risk disease using the current NCCN criteriaDavid Killock
Pageof 31

Showing results (191-200 of 304) with videos related to

Sort By:
Pageof 31
Nature Reviews. Clinical Oncology|November 28, 2018
Second elotuzumab triplet efficacious in MMDavid Killock
Nature Reviews. Rheumatology|February 6, 2013
Metabolic bone diseases: Building bone is best in glucocorticoid-induced osteoporosisDavid Killock
Nature Reviews. Clinical Oncology|August 13, 2014
Drug therapy: keeping rats in the dark sheds light on tamoxifen resistanceDavid Killock
Nature Reviews. Clinical Oncology|October 15, 2014
Lung cancer: alternative rearrangements--targeting ROS1 in NSCLCDavid Killock
Nature Reviews. Clinical Oncology|June 11, 2026
From ASCO 2026David Killock
Nature Reviews. Clinical Oncology|December 21, 2016
Liver cancer: Regorafenib - a new RESORCE in HCCDavid Killock
Nature Reviews. Clinical Oncology|November 3, 2016
In the news: From ESMO 2016David Killock
Nature Reviews. Urology|February 5, 2014
Kidney cancer: Sunitinib has similar efficacy irrespective of age in mRCCDavid Killock
Nature Reviews. Clinical Oncology|April 23, 2014
Chemotherapy: life gained, years lost?David Killock
Nature Reviews. Urology|March 19, 2014
Prostate cancer: substratification of intermediate-risk disease using the current NCCN criteriaDavid Killock
Pageof 31